Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Maintains Buy on Lyell Immunopharma, Lowers Price Target to $9

HC Wainwright & Co. analyst Mitchell Kapoor maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $11 to $9.
byBenzinga Newsdesk
March 2, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Mitchell Kapoor maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $11 to $9.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts